2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

1359 HDAC7 is necessary for hematopoietic stem and progenitor cell function

Bernadette Tiberi, Sara Meyer, PhD2, Robert L Bowman, PhD3
1 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
2 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States

Hematopoietic stem and progenitor cell (HSPC) identity and cell fate is largely controlled by the epigenetic landscape within each cell, influencing its response to the surrounding environment through coordinated gene expression. Histone acetylation is a reversible epigenetic modification known to take place at specific lysine residues on histone tails mainly in promoter and enhancer regions to control gene expression. Interestingly, members of the class IIa histone deacetylase (HDAC) family, including HDAC7, have intrinsically low enzymatic activity as compared to class I HDACs. Recent work show HDAC7 is overexpressed in acute erythrocytic leukemia and in subsets of leukemia stem cells, but a role for HDAC7 in normal HSPC has not been explored (PMID: 39277669; PMID: 27016502). While HDAC represent potential therapeutic targets in a variety of cancers including hematologic malignancies, patients have often experienced adverse side effects without receiving maximal therapeutic benefits from current HDAC inhibitors. Therefore, a better understanding of the role of HDACs, including HDAC7, in HSPCs is crucial for future translation of novel HDAC inhibitors into the clinic.

Using transgenic mice with conditional deletion of Hdac7 (Hdac7f/f and Hdac7Δ/Δ) early in hematopoiesis (Vav-iCre), we observed significantly reduced B and T cell populations in the blood and spleen, and conversely increased monocytes and granulocytes in the blood and bone marrow but otherwise seemingly healthy Hdac7Δ/Δ mice. Given that Hdac7 deletion results in multi-lineage defects, we hypothesize that Hdac7 regulates HSC self-renewal and HSPC differentiation through transcriptional and non-transcriptional functions and that perturbation of Hdac7 contributes to hematopoietic dysfunction. Adult 8-12-week-old bone marrow revealed Hdac7Δ/Δ mice have significantly reduced numbers of primitive HSC (CD150+CD48-CD34-CD135-Sca1+cKit+Lin-) and pre-megakaryocyte/erythroid cells (CD105low CD16/32lowCD150+CD41-/lowSca1-cKit+Lin-) but significantly increased pre-CFU-E (CD105highCD16/32-/lowCD150+CD41-/lowSca1-cKit+Lin-). These changes in Meg/Ery progenitors impact differentiation as Hdac7Δ/Δ mice have increased immunophenotypic Mk cells in the bone marrow and erythroid cell dysplasia in the periphery. Altogether, these data suggest that Hdac7 plays an important role across a spectrum of hematopoietic cell types, including the earliest HSC.

To further characterize the requirements of Hdac7 in HSC, we performed competitive transplants which showed an allele-dose-dependent decline in peripheral blood chimerism with Hdac7Δ/Δ cells accounting for less than 10% of the total peripheral blood in reconstituted mice. Serial transplantation of Hdac7Δ/Δ bone marrow cells showed a progressive decline in hematopoietic reconstitution with complete bone marrow failure and lethality in tertiary recipients. Additionally, Hdac7Δ/Δ HSC exhibited premature exhaustion after serial 5-flurouracil challenge. Altogether these data reveal that Hdac7 is a critical regulator of proper HSPC function.

Single-cell RNA sequencing (scRNA-seq) analyses failed to detect any primitive HSCs in Hdac7Δ/Δ bone marrow, consistent with immunophenotypic and functional studies. The earliest multipotent progenitors (MPP) had reduced expression of the immediate-early response transcription factor Egr1, Fos, and Jun and increased expression of cell cycle and proliferation pathway genes. These data suggest that the earliest defects can be seen transcriptionally in Hdac7Δ/Δ MPP which may be compensating for the lack of HSC. We also observed profound transcriptional dysregulation in erythroid progenitors which displayed megakaryopoiesis-promoting gene programs with a switch in key lineage-regulating transcription factors with Erg (Mk) increased and decreased Myb (Ery) suggesting that Hdac7 is important for repression of megakaryocyte-lineage programs in erythroid progenitors.

Overall, these data support previously unrecognized and central roles for Hdac7 in HSPC biology and cell fate decisions.

Bernadette Tiberi: No relevant conflicts of interest to declare.